Home>Topics>>Ariad Sees Heavy Drop Following Spontaneous FDA Approval
Ariad Sees Heavy Drop Following Spontaneous FDA Approval
Healthcare Sector and Stocks Analysis from Seeking Alpha
Wed, 19 Dec 2012
By Brian L. Wilson : Last Friday we saw a bearish move in shares of Ariad Pharmaceuticals (NASDAQ: ARIA ) on news that its drug Iclusig (ponatinib) was approved early by the FDA. The original PDUFA action date was in March 2013, but this early approval implies that the FDA saw quite a bit of ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.